Can a psychedelic drug help heal trauma? a small trial puts psilocybin to the test

NCT ID NCT07737054

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-stage pilot study is testing whether psilocybin, a psychedelic compound, can be safely combined with trauma-focused psychotherapy for people with post-traumatic stress disorder (PTSD). Thirteen participants will receive two doses of psilocybin in a controlled setting, along with preparatory and integration therapy sessions. The main goal is to check safety and tolerability, while also measuring changes in PTSD symptoms 30 days after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin, a naturally occurring psychedelic compound, given orally in two doses (15 mg and 25 mg) during therapy sessions
What this could lead to
If safe and promising, this could point toward a new treatment approach for PTSD that combines therapy with a psychedelic drug.
What could go wrong
This is a very early, small pilot study with only 13 people. It is designed mainly to check safety, not to prove the treatment works. Psychedelics can cause intense psychological effects and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST TRAUMATIC STRESS DISORDER (PTSD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tel Aviv Sourasky Medical Center

    RECRUITING

    Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.